These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32857657)

  • 1. ICER's Version of HTA Is Positioned to Guide U.S. Health Care Reform.
    Watkins JB
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1171. PubMed ID: 32857657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolution of ICER's review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER's reports.
    Ronquest NA; Paret K; Gould IG; Barnett CL; Mladsi DM
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1601-1612. PubMed ID: 34714108
    [No Abstract]   [Full Text] [Related]  

  • 3. HTA'd in the USA: A Comparison of ICER in the United States with NICE in England and Wales.
    Thokala P; Carlson JJ; Drummond M
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1162-1170. PubMed ID: 32857653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HTA and economics in the United States: a systematic review of ICER reports to evaluate trends, identify factors associated with recommendations, and understand implications.
    Kruzikas DT; Malone DC; Pham S; Reinsch TK; Akehurst R
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1548-1557. PubMed ID: 33251996
    [No Abstract]   [Full Text] [Related]  

  • 5. The use of real-world evidence in ICER's scoping process and clinical evidence assessments.
    Jiao B; Veenstra DL; Lee W; Carlson JJ; Devine B
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1590-1595. PubMed ID: 33251999
    [No Abstract]   [Full Text] [Related]  

  • 6. Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments?
    Cohen JT; Silver MC; Ollendorf DA; Neumann PJ
    Value Health; 2019 Dec; 22(12):1396-1401. PubMed ID: 31806196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examining US commercial health plans' use of The Institute for Clinical and Economic Review's reports in specialty drug coverage decisions.
    Chambers JD; Enright DE; Panzer AD; Cohen JT; Ollendorf DA; Neumann PJ
    J Manag Care Spec Pharm; 2023 Mar; 29(3):257-264. PubMed ID: 36840954
    [No Abstract]   [Full Text] [Related]  

  • 8. Do Research Groups Align on an Intervention's Value? Concordance of Cost-Effectiveness Findings Between the Institute for Clinical and Economic Review and Other Health System Stakeholders.
    Sussman M; Yu JC; Menzin J
    Appl Health Econ Health Policy; 2020 Aug; 18(4):477-489. PubMed ID: 31919779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
    J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
    [No Abstract]   [Full Text] [Related]  

  • 10. ICER's Revised Value Assessment Framework for 2017-2019: A Critique.
    Neumann PJ; Cohen JT
    Pharmacoeconomics; 2017 Oct; 35(10):977-980. PubMed ID: 28791663
    [No Abstract]   [Full Text] [Related]  

  • 11. Health technology assessment in Saudi Arabia.
    Al-Aqeel S
    Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):393-402. PubMed ID: 29733227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can We Develop Sustainable and Sharable Cost-Effectiveness Models for Value Assessment in the U.S. Health Care System?
    Chapman RH; Kumar V
    J Manag Care Spec Pharm; 2019 May; 25(5):521-524. PubMed ID: 31039064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HEALTH TECHNOLOGY ASSESSMENT IN CENTRAL, EASTERN, AND SOUTH EUROPEAN COUNTRIES: CROATIA.
    Huic M; Tandara Hacek R; Svajger I
    Int J Technol Assess Health Care; 2017 Jan; 33(3):376-383. PubMed ID: 28803589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HEALTH TECHNOLOGY ASSESSMENT IN TURKEY.
    Kahveci R; Koç EM; Küçük EÖ
    Int J Technol Assess Health Care; 2017 Jan; 33(3):402-408. PubMed ID: 28595660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can transparency save health care?
    Sipkoff M
    Manag Care; 2004 Mar; 13(3):28-32. PubMed ID: 15074152
    [No Abstract]   [Full Text] [Related]  

  • 16. An equity framework for health technology assessments.
    Culyer AJ; Bombard Y
    Med Decis Making; 2012; 32(3):428-41. PubMed ID: 22065143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. German health care system in transition. The difficult way to balance cost containment and solidarity.
    von der Schulenburg JM
    Eur J Health Econ; 2005 Jun; 6(2):183-7. PubMed ID: 15909198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health and Social Care Bill 2011: a legal basis for charging and providing fewer health services to people in England.
    Pollock AM; Price D; Roderick P
    BMJ; 2012 Mar; 344():e1729. PubMed ID: 22403268
    [No Abstract]   [Full Text] [Related]  

  • 19. The Structure and Financing of Health Care Systems Affected How Providers Coped With COVID-19.
    Waitzberg R; Quentin W; Webb E; Glied S
    Milbank Q; 2021 Jun; 99(2):542-564. PubMed ID: 34161635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HTA goes Europe: European collaboration on joint assessment and methodological issues becomes reality].
    Nachtnebel A; Mayer J; Erdös J; Lampe K; Kleijnen S; Schnell-Inderst P; Wild C
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):291-9. PubMed ID: 26354129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.